FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to compound 2-(3-(2-methyl-6-(p-tolyl)pyridin-3-yl)ureido)benzenesulfonamide of formula below, which has the ability to inhibit activity and/or overexpression of the carbonic anhydrase IX enzyme. Invention also relates to use of said compound for producing a drug for inhibiting activity and/or overexpression of the carbonic anhydrase IX enzyme and for producing a drug, suitable for treating and/or preventing diseases or disorders characterized by overexpression of the carbonic anhydrase IX enzyme, and a pharmaceutical composition containing it.
EFFECT: there are presented 2-(3-(2-methyl-6-(p-tolyl)pyridin-3-yl)ureido)benzenesulfonamide and derivatives as carbonic anhydrase IX inhibitors for treating cancer.
8 cl, 5 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TARGETING CANCER TUMOURS BY APPLICATION OF INHIBITORS OF CARBONIC ANHYDRASE IX ISOFORMS | 2011 |
|
RU2568115C2 |
| MDM2 INHIBITORS AND COMBINATIONS THEREOF | 2016 |
|
RU2740091C2 |
| 5-[[4-[[MORPHOLIN-2-YL]METHYLAMINO]-5-(TRIFLUOROMETHYL)-2-PYRIDYL]AMINO]PYRAZINE-2-CARBONITRILE, THERAPEUTIC USES THEREOF | 2013 |
|
RU2659786C2 |
| 5-(PYRIDINE-2-YLAMINO)-PYRASIN-2-CARBONITRILE COMPOUNDS AND THEIR THERAPEUTIC APPLICATION | 2012 |
|
RU2641693C2 |
| USE OF ALPHAVIRUS IN PREPARATION OF ANTITUMOR DRUGS | 2015 |
|
RU2693938C2 |
| METHODS OF TREATING CANCER, HAVING HEMIZYGOUS LOSS OF TP53 | 2016 |
|
RU2721953C2 |
| METHOD FOR DETERMINING PROBABILITY OF THERAPEUTIC RESPONSE ON CANCER THERAPY WITH CARDIAC GLYCOSIDE | 2008 |
|
RU2508114C2 |
| KIT FOR DETECTING PROBABILITY OF THERAPEUTIC RESPONSE TO ANTI-CANCER CHEMOTHERAPY WITH CARDIAC GLYCOSIDE | 2008 |
|
RU2571687C2 |
| DOSAGE REGIMEN FOR AN ALPHA-ISOFORM SELECTIVE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR | 2014 |
|
RU2680246C1 |
| COMPOSITIONS, CONTAINING (S)-2-AMINO-1-(4-CHLOROPHENYL)-1-[4-(1H-PYRAZOL-4-YL)PHENYL]ETHANOL AS MODULATORS OF PROTEINKINASES | 2008 |
|
RU2527151C2 |
